Adocia : Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets

5053334f-10c1-4e70-bd34-88665543f9e1.pdf

PRESS RELEASE

Half year report on Adocia's liquidity agreement with Kepler Capital Markets

Lyon, France, January 8, 2016 - Under the liquidity agreement entrusted by Adocia to Kepler Capital Markets, the following resources were listed on the liquidity account as at December 31, 2015 :

• 4,185 shares of Adocia and

• 132,740.22 euros in cash.

  
  

  At the last half year report dated June 30, 2015, the following resources were listed on the liquidity account:

  
  

• 2,257 shares of Adocia and

• 83,378.96 euros in cash.

About Adocia:

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia's insulin formulation portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia's clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a fast-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a fast-acting insulin analog (BioChaperone Combo). Adocia is also developing a concentrated, rapid-acting formulation of human insulin (HinsBet U500).

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro programs.

Adocia's extended, early-stage programs include innovative monoclonal antibody formulations, featuring two ongoing collaborations programs with major pharmaceutical companies in the field, and the delivery of anticancer drugs using the proprietary DriveIn® nanotechnology platform.

Adocia aims to deliver "Innovative medicine for everyone, everywhere."

To learn more about Adocia, please visit us at www.adocia.com

For more information please contact:

Adocia Gérard Soula Chairman and CEO of Adocia contactinvestisseurs@adocia.com Tel.: +33 4 72 610 610

Adocia Press Relations ALIZE RP Caroline Carmagnol caroline@alizerp.comadocia@alizerp.com Tel.: + 33 1 44 54 36 61